JOP20210225A1 - تركيبة دوائية لعلاج الأورام الخبيثة ذات الخلايا البائية - Google Patents

تركيبة دوائية لعلاج الأورام الخبيثة ذات الخلايا البائية

Info

Publication number
JOP20210225A1
JOP20210225A1 JOP/2021/0225A JOP20210225A JOP20210225A1 JO P20210225 A1 JOP20210225 A1 JO P20210225A1 JO P20210225 A JOP20210225 A JO P20210225A JO P20210225 A1 JOP20210225 A1 JO P20210225A1
Authority
JO
Jordan
Prior art keywords
treatment
combination therapy
cell malignancies
cell malignancy
combination
Prior art date
Application number
JOP/2021/0225A
Other languages
English (en)
Inventor
Sriram Balasubramanian
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of JOP20210225A1 publication Critical patent/JOP20210225A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

يتم توفير طرق لعلاج الورم الخبيث ذي الخلايا البائية والطفرات الجينية الممكن استخدامها لتحديد المشاركين في الدراسة الذين سيستجيبون لعلاج ورم خبيث في الخلية البائية باستخدام توليفة تضم إبروتينيب وجسم مضاد لـ PD-1.
JOP/2021/0225A 2019-02-15 2020-02-14 تركيبة دوائية لعلاج الأورام الخبيثة ذات الخلايا البائية JOP20210225A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806148P 2019-02-15 2019-02-15
PCT/IB2020/051270 WO2020165861A1 (en) 2019-02-15 2020-02-14 Combination therapy for treatment of b-cell malignancies

Publications (1)

Publication Number Publication Date
JOP20210225A1 true JOP20210225A1 (ar) 2023-01-30

Family

ID=69740437

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0225A JOP20210225A1 (ar) 2019-02-15 2020-02-14 تركيبة دوائية لعلاج الأورام الخبيثة ذات الخلايا البائية

Country Status (15)

Country Link
US (1) US20200262925A1 (ar)
EP (1) EP3923945A1 (ar)
JP (1) JP2022520429A (ar)
KR (1) KR20210129111A (ar)
CN (1) CN113766918A (ar)
AU (1) AU2020222359A1 (ar)
BR (1) BR112021015964A2 (ar)
CA (1) CA3129593A1 (ar)
EA (1) EA202192256A1 (ar)
IL (1) IL285458A (ar)
JO (1) JOP20210225A1 (ar)
MA (1) MA54941A (ar)
MX (1) MX2021009821A (ar)
SG (1) SG11202108770TA (ar)
WO (1) WO2020165861A1 (ar)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150141971A (ko) * 2013-04-08 2015-12-21 파마싸이클릭스 엘엘씨 이브루티닙 병용 요법
AU2014339816B2 (en) * 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
WO2016128912A1 (en) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
CA2950640A1 (en) * 2015-12-04 2017-06-04 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
EP3500299B1 (en) * 2016-08-19 2023-12-13 BeiGene Switzerland GmbH Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer

Also Published As

Publication number Publication date
US20200262925A1 (en) 2020-08-20
MA54941A (fr) 2021-12-22
JP2022520429A (ja) 2022-03-30
WO2020165861A1 (en) 2020-08-20
EP3923945A1 (en) 2021-12-22
EA202192256A1 (ru) 2021-10-27
CA3129593A1 (en) 2020-08-20
KR20210129111A (ko) 2021-10-27
CN113766918A (zh) 2021-12-07
IL285458A (en) 2021-09-30
BR112021015964A2 (pt) 2021-10-05
AU2020222359A1 (en) 2021-09-02
SG11202108770TA (en) 2021-09-29
MX2021009821A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
MX2020012286A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2022006701A (es) Terapia combinada para el tratamiento de neoplasias malignas.
MX2022008868A (es) Tratamiento del cancer con tg02.
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
SG10201902594QA (en) Peptidomimetic macrocycles and uses thereof
NZ725595A (en) Compounds for treating brain cancer
ZA201803162B (en) Combination therapy for treating malignancies
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
MX2020001727A (es) Terapia de combinacion.
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
IL283298A (en) Methods for dosage and treatment of B cell malignancies in adoptive cell therapy
NZ760756A (en) Biomarkers for the diagnosis and treatment of fibrotic lung disease
MX2021003262A (es) Metodos de tratamiento.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
MX2021009821A (es) Terapia de combinación para el tratamiento de neoplasias malignas de células b.
MX2021006778A (es) Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
PH12020550587A1 (en) Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2021005189A (es) Uso de tivozanib para tratar sujetos con cancer refractario.